neoplasms

Promoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females.

Skeletal muscle atrophy during cancer-induced cachexia remains a significant challenge in cancer management. Mitochondrial defects precede muscle mass and functional losses in models of cancer cachexia (CC). We hypothesized targeting Opa1-a key regulator of mitochondrial fusion-can attenuate LLC-induced CC outcomes....

๐Ÿ—“๏ธ 2025-08-11
Read MorePromoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females.

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...

๐Ÿ—“๏ธ 2025-07-29
๐Ÿ“ฐ Publication: Cell
Read MoreVagal blockade of the brain-liver axis deters cancer-associated cachexia.

Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

AI-driven automated body composition analysis (BCA) may provide quantitative prognostic biomarkers derived from routine staging CTs. This two-centre study evaluates the prognostic value of these volumetric markers for overall survival in lung cancer patients. Lung cancer cohorts from Hospital A...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreExploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

Cancer therapy and cachexia.

A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Clinical Investigation
Read MoreCancer therapy and cachexia.

Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.

Patients with sarcopenia and elevated body mass index (BMI) are at high risk of platinum-associated adverse events (AEs). This study examines the association between sarcopenia, BMI, and AEs in patients with non-small cell lung cancer (NSCLC). This retrospective cohort study...

๐Ÿ—“๏ธ 2025-07-30
๐Ÿ“ฐ Publication: Journal Of The National Comprehensive Cancer Network
Read MoreSarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia. This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer...

๐Ÿ—“๏ธ 2025-07-30
๐Ÿ“ฐ Publication: Journal Of The National Comprehensive Cancer Network
Read MoreOlanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

In cancer cachexia, the presence of a tumor triggers systemic metabolic disruption that leads to involuntary body weight loss and accelerated mortality in affected patients. Here, we conducted transcriptomic and epigenomic profiling of the liver in various weight-stable cancer and...

๐Ÿ—“๏ธ 2025-07-18
๐Ÿ“ฐ Publication: Cell
Read MoreFunctional liver genomics identifies hepatokines promoting wasting in cancer cachexia.

B0092 tumor-bearing mice are a new model for the study of cachexia in head and neck cancer.

Introduction: Head and neck cancer (HNC) accounts for ~4% of all cancers but causes ~15,000 deaths annually in the U.S. Over 40% of HNC patients present with cachexia, a severe comorbidity associated with skeletal muscle defects, worsened treatment response, and...

๐Ÿ—“๏ธ 2025-07-21
๐Ÿ“ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreB0092 tumor-bearing mice are a new model for the study of cachexia in head and neck cancer.

Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.

The discovery of immune checkpoints links autoimmunity and cancer, with thymus atrophy reportedly causing autoimmune multiorgan inflammation. The impact of cancer cachexia on thymic involution and its clinical significance remains unclear. This study aimed to investigate this effect and its...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and Toxicity.

High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.

In cancer cachexia, cytokine release by tumours causes weight loss, decreased therapeutic efficacy, and worsened prognosis. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and fibroblast inducible factor 14 (Fn14) are cancer cachexia-related proteins; however, their expression in oesophageal squamous...

๐Ÿ—“๏ธ 2025-07-15
๐Ÿ“ฐ Publication: British Journal Of Cancer
Read MoreHigh expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance.

The Combination of Fat Distribution and BMI Redefines Obesity: Result From NHANES.

Body mass index (BMI) has well-recognized limitations, particularly in the context of the 'obesity paradox', where higher BMI does not consistently evaluate adverse outcomes. These limitations underscore the need for alternative approaches. This study aimed to redefine obesity using anthropometric...

๐Ÿ—“๏ธ 2025-08-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreThe Combination of Fat Distribution and BMI Redefines Obesity: Result From NHANES.

The role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk.

The growing population of childhood cancer survivors (CCSs) experiences a large burden of comorbidities, including a markedly increased risk of diabetes mellitus. Among CCSs, prediabetes and diabetes are important risk factors for subsequent cardiovascular disease, which is a leading cause...

๐Ÿ—“๏ธ 2025-07-15
๐Ÿ“ฐ Publication: Cancer
Read MoreThe role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk.

GDF15: from biomarker to target in cancer cachexia.

Most patients with advanced cancer suffer from cachexia, a complex metabolic disorder characterized by unintentional body weight loss that diminishes their quality of life and reduces the effectiveness of therapies. Currently, effective treatments for cachexia remain elusive. Growth differentiation factor...

๐Ÿ—“๏ธ 2025-07-09
๐Ÿ“ฐ Publication: Trends In Cancer
Read MoreGDF15: from biomarker to target in cancer cachexia.

Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling...

๐Ÿ—“๏ธ 2025-07-03
๐Ÿ“ฐ Publication: Journal Of Advanced Research
Read MoreScutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!